Ixekizumab
- HY-P9924
- 皓元医药
- 上海市
- 一周内
- 5mg
- 6800 元
- 2022-07-23 11:37:26
上海皓元生物医药科技有限公司
- CAS号
- 1143503-69-8
MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。
Ixekizumab
产品活性：Ixekizumab 是一种人源化 IgG4 单克隆抗体，可选择性结合和中和白细胞介素 IL-17A (KD<3 pM)。Ixekizumab 直接阻断 IL-17A 与 IL-17RA 的结合，但不与其他 IL-17 家族成员结合。Ixekizumab 用于中重度斑块型银屑病的研究。
研究领域：Immunology/Inflammation
作用靶点：Interleukin Related
In Vitro: The equilibrium KD of Ixekizumab for human and cynomolgus monkey IL-17A were 1.8 pM and 0.8 pM, respectively. Ixekizumab also bound to rabbit IL-17A, but the affinity was lower, and the binding was heterogeneous (KD of 1.3 nM and 14 nM). Ixekizumab shows no binding to either mouse or rat IL-17A.
Ixekizumab (0.1-10000 pM) inhibits human IL-17A- or human IL-17A/F heterodimer-induced growth-regulated oncogene (GRO)α secretion from HT-29 cells in a dose-dependent fashion. Ixekizumab inhibits cynomolgus monkey IL-17A-induced GROα secretion from HT-29 cells in a dose-dependent fashion.
In Vivo: Ixekizumab (0.001-1 mg/kg; i.v.) is able to decrease human IL-17A-induced keratinocyte chemoattractant (KC) secretion in the plasma of the C57BL/6 mice in a dose-dependent manner.
In male cynomolgus monkeys, following IV administration of 1 mg/kg, Ixekizumab is eliminated with a mean half-life of 6.5 days. After SC administration of 1 mg/kg, Ixekizumab reaches an average maximal plasma concentration of 11.1 µg/mL ~72 hours postdose. The mean elimination half-life following the SC injection was 10.3 days.
相关产品：Resatorvid | Disulfiram | Deucravacitinib | Apilimod | Tocilizumab | LMT-28 | Hydrocortisone hemisuccinate | Muscone | Diacerein | Dupilumab | APY0201 | Vidofludimus | SC144 | Semapimod tetrahydrochloride | Madecassic acid | Neochlorogenic acid | RCGD423 | Y-320 | Mulberroside A | Ginsenoside Rc | Pectolinarin | Methylthiouracil | VGX-1027 | AX-024 | IL-17A antagonist 1 | Ossirene | Secukinumab | AF12198
品牌介绍:
• MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；
• 10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
• 设有专业的实验中心和严格的质控、验证体系；
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
• 产品的生物活性多经各国客户实验验证；
• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
• 专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
• 与世界各大制药公司及知名科研机构建立了长期的合作。
